These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 18304810)
1. Phenylglycine and phenylalanine derivatives as potent and selective HDAC1 inhibitors (SHI-1). Wilson KJ; Witter DJ; Grimm JB; Siliphaivanh P; Otte KM; Kral AM; Fleming JC; Harsch A; Hamill JE; Cruz JC; Chenard M; Szewczak AA; Middleton RE; Hughes BL; Dahlberg WK; Secrist JP; Miller TA Bioorg Med Chem Lett; 2008 Mar; 18(6):1859-63. PubMed ID: 18304810 [TBL] [Abstract][Full Text] [Related]
2. SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). Methot JL; Hamblett CL; Mampreian DM; Jung J; Harsch A; Szewczak AA; Dahlberg WK; Middleton RE; Hughes B; Fleming JC; Wang H; Kral AM; Ozerova N; Cruz JC; Haines B; Chenard M; Kenific CM; Secrist JP; Miller TA Bioorg Med Chem Lett; 2008 Dec; 18(23):6104-9. PubMed ID: 18951790 [TBL] [Abstract][Full Text] [Related]
3. Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2). Witter DJ; Harrington P; Wilson KJ; Chenard M; Fleming JC; Haines B; Kral AM; Secrist JP; Miller TA Bioorg Med Chem Lett; 2008 Jan; 18(2):726-31. PubMed ID: 18060775 [TBL] [Abstract][Full Text] [Related]
4. Parallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimization. Kattar SD; Surdi LM; Zabierek A; Methot JL; Middleton RE; Hughes B; Szewczak AA; Dahlberg WK; Kral AM; Ozerova N; Fleming JC; Wang H; Secrist P; Harsch A; Hamill JE; Cruz JC; Kenific CM; Chenard M; Miller TA; Berk SC; Tempest P Bioorg Med Chem Lett; 2009 Feb; 19(4):1168-72. PubMed ID: 19138845 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and antitumor evaluation of histone deacetylase inhibitors with L-phenylglycine scaffold. Zhang Y; Li X; Hou J; Huang Y; Xu W Drug Des Devel Ther; 2015; 9():5553-67. PubMed ID: 26504374 [TBL] [Abstract][Full Text] [Related]
6. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). Methot JL; Chakravarty PK; Chenard M; Close J; Cruz JC; Dahlberg WK; Fleming J; Hamblett CL; Hamill JE; Harrington P; Harsch A; Heidebrecht R; Hughes B; Jung J; Kenific CM; Kral AM; Meinke PT; Middleton RE; Ozerova N; Sloman DL; Stanton MG; Szewczak AA; Tyagarajan S; Witter DJ; Secrist JP; Miller TA Bioorg Med Chem Lett; 2008 Feb; 18(3):973-8. PubMed ID: 18182289 [TBL] [Abstract][Full Text] [Related]
7. Identification of novel isoform-selective inhibitors within class I histone deacetylases. Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486 [TBL] [Abstract][Full Text] [Related]
8. Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). Schäfer S; Saunders L; Eliseeva E; Velena A; Jung M; Schwienhorst A; Strasser A; Dickmanns A; Ficner R; Schlimme S; Sippl W; Verdin E; Jung M Bioorg Med Chem; 2008 Feb; 16(4):2011-33. PubMed ID: 18054239 [TBL] [Abstract][Full Text] [Related]
9. Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors. Andrews DM; Stokes ES; Carr GR; Matusiak ZS; Roberts CA; Waring MJ; Brady MC; Chresta CM; East SJ Bioorg Med Chem Lett; 2008 Apr; 18(8):2580-4. PubMed ID: 18378449 [TBL] [Abstract][Full Text] [Related]
10. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431 [TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. Wittich S; Scherf H; Xie C; Brosch G; Loidl P; Gerhäuser C; Jung M J Med Chem; 2002 Jul; 45(15):3296-309. PubMed ID: 12109913 [TBL] [Abstract][Full Text] [Related]
12. Design and optimization of novel hydroxamate-based histone deacetylase inhibitors of Bis-substituted aromatic amides bearing potent activities against tumor growth and metastasis. Yang F; Zhang T; Wu H; Yang Y; Liu N; Chen A; Li Q; Li J; Qin L; Jiang B; Wang X; Pang X; Yi Z; Liu M; Chen Y J Med Chem; 2014 Nov; 57(22):9357-69. PubMed ID: 25360834 [TBL] [Abstract][Full Text] [Related]
13. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033 [TBL] [Abstract][Full Text] [Related]
14. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects. Liao V; Liu T; Codd R Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I). Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738 [TBL] [Abstract][Full Text] [Related]
16. The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors. Hamblett CL; Methot JL; Mampreian DM; Sloman DL; Stanton MG; Kral AM; Fleming JC; Cruz JC; Chenard M; Ozerova N; Hitz AM; Wang H; Deshmukh SV; Nazef N; Harsch A; Hughes B; Dahlberg WK; Szewczak AA; Middleton RE; Mosley RT; Secrist JP; Miller TA Bioorg Med Chem Lett; 2007 Oct; 17(19):5300-9. PubMed ID: 17761416 [TBL] [Abstract][Full Text] [Related]
17. Structure-based optimization of click-based histone deacetylase inhibitors. Hou J; Feng C; Li Z; Fang Q; Wang H; Gu G; Shi Y; Liu P; Xu F; Yin Z; Shen J; Wang P Eur J Med Chem; 2011 Aug; 46(8):3190-200. PubMed ID: 21621883 [TBL] [Abstract][Full Text] [Related]
18. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model. Shindoh N; Mori M; Terada Y; Oda K; Amino N; Kita A; Taniguchi M; Sohda KY; Nagai K; Sowa Y; Masuoka Y; Orita M; Sasamata M; Matsushime H; Furuichi K; Sakai T Int J Oncol; 2008 Mar; 32(3):545-55. PubMed ID: 18292931 [TBL] [Abstract][Full Text] [Related]
19. Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties. Kinzel O; Llauger-Bufi L; Pescatore G; Rowley M; Schultz-Fademrecht C; Monteagudo E; Fonsi M; Gonzalez Paz O; Fiore F; Steinkühler C; Jones P J Med Chem; 2009 Jun; 52(11):3453-6. PubMed ID: 19441846 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors. Thaler F; Colombo A; Mai A; Amici R; Bigogno C; Boggio R; Cappa A; Carrara S; Cataudella T; Fusar F; Gianti E; di Ventimiglia SJ; Moroni M; Munari D; Pain G; Regalia N; Sartori L; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C; Varasi M J Med Chem; 2010 Jan; 53(2):822-39. PubMed ID: 20017493 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]